Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G protein-coupled receptor 12 (GPR12)
- Target
- GPR12
- Molecular classification
- G protein-coupled receptor, Receptor, Class A (Rhodopsin-like) GPCR
01
Overview
G protein-coupled receptor 12 (GPR12) is an orphan member of the rhodopsin-like (class A) GPCR family, characterized by constitutive activity and coupling primarily to the G~s~ subunit, facilitating cAMP generation and downstream signaling. Predominantly expressed in the thalamus, GPR12 contributes to neural development, signal transduction, and may influence both neuronal differentiation and cancer cell migration. Endogenous lysophospholipids, including sphingosyl-phosphorylcholine, activate GPR12, leading to diverse cellular outcomes. Despite its pharmacological promise, GPR12 lacks well-characterized endogenous or synthetic modulators and remains understudied as a direct drug target. Its close relationship and sequence homology with GPR3 and GPR6 warrant caution in interpreting functional studies due to overlap in expression and potential compensatory mechanisms
- Other names
- GPCR12GPCR21PPP1R84protein phosphatase 1, regulatory subunit 84FLJ18149FLJ97704MGC138349MGC138351
02
Mechanism of action
Agonist binding can stimulate cAMP production via G~s~ activation Modulation by sphingosylphosphorylcholine (SPC) alters calcium signaling and cellular migration Cannabidiol acts as a modulator; fingolimod may act antagonistically by restoring PP2A expression and inhibiting SPC-induced functions
03
Biological functions
Signal transductionRegulation of cAMP synthesis (adenylate cyclase activation)NeurogenesisNeurite outgrowthCell proliferationIntracellular calcium ion homeostasis
04
Disease associations
Cancer (involved in migration and apoptosis in certain cancer cells, such as esophageal and hypopharyngeal cancer)Neurodevelopmental disorders (possible, but not fully established)Other (potential roles in inflammation and neural differentiation, but not clearly defined)
05
Safety considerations
Lack of selective ligands or drugs for GPR12 creates challenges in therapeutic targeting and risk assessmentPossible off-target effects and functional redundancy with GPR3 and GPR6 complicate preclinical and clinical evaluation
06
Interacting drugs
Cannabidiol (CBD, phytocannabinoid, exogenous ligand; modulates GPR12 activity)
1 more in the full profile.
Beyond the preview
Go deeper on G protein-coupled receptor 12 (GPR12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G protein-coupled receptor 12 (GPR12).